By: Jessica E. Lessin
It’s hard to think of a company that faces a bigger perception gap than Anduril. Talk to investors in Silicon Valley, and they will be clamoring to get in on its next round—last priced at $30 billion. Talk to generals and others in the traditional defense industry, and they’ll ask whether the ...















